Neumora Therapeutics, Inc. (NMRA) Stock Forecast
NMRA analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.22 / 5 from 9 analysts
- Price target
- $6.14 average of analyst targets
- Upside to target
- +1,196.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.19
- 52-week range
- $0.35 – $3.59
NMRA analyst ratings
9 analystsNumber of analysts at each rating.
NMRA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NMRA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.21 | −$0.17 | −$0.35 | +45.1% | 9 |
| Current fiscal year (2026) | −$0.87 | −$0.94 | −$0.65 | −$1.45 | +39.9% | 9 |
| Next fiscal year (2027) | −$0.67 | −$0.97 | −$0.33 | −$0.87 | +23.2% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NMRA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 9 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 9 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
NMRA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NMRA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.21 | −$0.19 | −$0.19 | −$0.19 | −7.3% | 4 up · 2 down |
| Current fiscal year (2026) | −$0.92 | −$0.91 | −$0.87 | −$0.87 | −$0.87 | −5.3% | 5 up · 2 down |
| Next fiscal year (2027) | −$0.77 | −$0.73 | −$0.67 | −$0.67 | −$0.67 | −13.5% | 5 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NMRA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NMRA beat in 6 of 12.
What analysts expect from NMRA
9 analysts cover Neumora Therapeutics; their consensus rating is buy (4.22 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.14, 1,196.0% above the latest close of $0.47. Analysts expect earnings of −$0.87 per share for 2026, +39.9% from a year earlier. For 2027 the average estimate is −$0.67 per share. Neumora Therapeutics beat the EPS estimate in 6 of the last 12 quarters.
Related: NMRA income statement, NMRA key metrics, NMRA chart. See the NMRA stock overview for the latest quote and news.
NMRA forecast FAQ
What is Neumora Therapeutics's price target?
The average analyst price target for Neumora Therapeutics is $6.14, 1,196.0% above the latest close of $0.47.
Is Neumora Therapeutics a buy, hold or sell?
Of 9 analysts covering Neumora Therapeutics, 5 rate it a strong buy, 2 a buy, 1 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Neumora Therapeutics's EPS forecast?
Analysts forecast −$0.87 per share for 2026 (range −$0.94 to −$0.65); for 2027 the estimate is −$0.67.
When does Neumora Therapeutics report earnings?
Neumora Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.19.
Does Neumora Therapeutics usually beat earnings estimates?
Neumora Therapeutics reported EPS at or above the analyst estimate in 6 of the last 12 quarters.